[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cogent Biosciences Inc (COGT)

Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,826,598
  • Shares Outstanding, K 170,868
  • Annual Sales, $ 0 K
  • Annual Income, $ -328,940 K
  • EBIT $ -362 M
  • EBITDA $ -361 M
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.93

Options Overview Details

View History
  • Implied Volatility 71.04% (+2.23%)
  • Historical Volatility 42.71%
  • IV Percentile 12%
  • IV Rank 4.51%
  • IV High 370.26% on 07/03/25
  • IV Low 56.91% on 01/21/26
  • Expected Move (DTE 3) 2.08 (6.06%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 1,257
  • Volume Avg (30-Day) 772
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 30,382
  • Open Int (30-Day) 27,005
  • Expected Range 32.29 to 36.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.55
  • Number of Estimates 7
  • High Estimate $-0.44
  • Low Estimate $-0.66
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) -3.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.54 +2.95%
on 05/12/26
37.99 -9.11%
on 04/20/26
-1.84 (-5.06%)
since 04/10/26
3-Month
32.70 +5.60%
on 03/20/26
40.45 -14.64%
on 02/25/26
-2.19 (-5.96%)
since 02/12/26
52-Week
4.55 +658.90%
on 05/19/25
43.73 -21.04%
on 12/08/25
+29.40 (+573.10%)
since 05/12/25

Most Recent Stories

More News
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings   Preclinical...

COGT : 34.53 (+1.26%)
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation...

COGT : 34.53 (+1.26%)
Cogent Biosciences: The Pipeline Distraction That Might Obscure What Actually Matters Tomorrow

Barchart Research What to Expect from COGT Earnings COGT Generated May 4, 2026 Current Price $36.73 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 17.24% Cogent Biosciences: The Pipeline...

COGT : 34.53 (+1.26%)
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 34.53 (+1.26%)
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors ...

COGT : 34.53 (+1.26%)
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GIST Bezuclastinib...

COGT : 34.53 (+1.26%)
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

WALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 34.53 (+1.26%)
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms 99% of patients achieve >50% reduction in serum tryptase...

COGT : 34.53 (+1.26%)
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastinib...

COGT : 34.53 (+1.26%)
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 34.53 (+1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 36.28
2nd Resistance Point 35.65
1st Resistance Point 34.87
Last Price 34.53
1st Support Level 33.46
2nd Support Level 32.83
3rd Support Level 32.05

See More

52-Week High 43.73
Last Price 34.53
Fibonacci 61.8% 28.76
Fibonacci 50% 24.14
Fibonacci 38.2% 19.52
52-Week Low 4.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.